Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.38%
$3.25
68% positive prob.
5-Day Prediction
+7.47%
$3.45
68% positive prob.
20-Day Prediction
+1.72%
$3.27
65% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +1.38% | +7.47% | +1.72% | 36.8% | Pending |
| Q2 2026 | SELL | -22.03% | -17.98% | -29.05% | 91.8% | Pending |
| Q1 2026 | SELL | -22.15% | -19.71% | -29.23% | 100.0% | -13.95% |
| Q4 2025 | BUY | +3.33% | +11.79% | +3.00% | 96.6% | -15.05% |
SEC 8-K filings with transcript text
Nov 12, 2026 · 37% conf.
1D
+1.38%
$3.25
Act: -27.42%
5D
+7.47%
$3.45
20D
+1.72%
$3.27
2 g086026_ex99-1.htm
Exhibit 99.1
Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption
New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy
Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities
BOCA RATON, Fla., November 12, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026.
Highlights included:
●Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer.
●Gross profit increased to $3.3 million from $2.7 million in the third quarter of 2025 and gross margin improved to 55% from 39.1% in the prior-year period.
●Shipped 26 systems, including eight carried over from the second quarter of 2026 due to financing approval timing, compared with 16 in the prior-year period. Excluding those eight systems, 18 systems were shipped during the quarter, compared with six shipments to customers other than the Company’s historically largest customer in the third quarter of 2025.
●Continued physician education initiatives and expanded customer relationships, including initial system purchases by two large private equity-backed dermatology groups.
●Launched TreatSkinCancer.com, a consumer education resource designed to increase awareness of skin cancer treatment options, complementing the Company’s ongoing physician education initiatives.
●Advanced international market-development activities across Asia-Pacific, including Australia, New Zealand, China and Hong Kong.
●Subsequent to quarter end, placed the Company’s 1,000th SRT system, marking an important commercial milestone.
Management Commentary
"Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability," said Joseph Sardano, Chairman and Chief Executive Officer. “With dedicated reimbursement codes now in effect, our conversations with physicians are increasingly focused on how to bring SRT into their practices.
“Our vision is to make SRT a more widely understood and accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer. We are expanding physician education and patient awareness, including through TreatSkinCancer.com, while pursuing opportunities internationally and developing additional revenue streams tied to system utilization, software and services. The recent sale of our 1,000th SRT system is a milestone I am particularly proud of.
“We have spent years advancing the technology and growing our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business. Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business,” concluded Sardano.
Third Quarter 2026 Financial Results
Revenues were $6.0 million compared with $6.9 million for the quarter ended September 30, 2025, a decrease of $0.9 million, or 13.0%. The revenue decrease primarily reflected a shift in product mix toward lower-priced SRT-100 systems versus higher-priced SRT-100 Vision systems, resulting in a lower average selling price per unit, as well as the absence of sales to a historically large customer. In addition, three systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements compared to zero in the prior year period, for which revenue is recognized over the term of the agreement rather than at the time of shipment.
Unit shipments increased year-over-year to 26 systems, including
eight carried over from the second quarter of 2026, compared with 16 systems in the prior-year period.
Cost of sales was $2.7 million compared to $4.2 million for the quarter ended September 30, 2025, a decrease of $1.5 million, or 35.7%. The decrease in cost of sales was primarily related to the product mix, including a higher proportion of SRT-100 units shipped compared to SRT-100 Vision units shipped, as SRT-100 units have a lower average cost per unit.
Gross profit was $3.3 million compared to $2.7 million for the three months ended September 30, 2025, an increase of $0.6 million, or 22.2%. Overall gross profit percentage was 55%, compared to 39.1% in the corresponding period in 2025. The increase in gross profit and margin was primarily driven by product mix, including a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-
Aug 13, 2026 · 92% conf.
1D
-22.03%
$2.46
Act: -9.49%
5D
-17.98%
$2.59
20D
-29.05%
$2.24
2 g085863_ex99-1.htm
Exhibit 99.1
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
Commercial Momentum Builds Following CPT Code Implementation
Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing
CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT
Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets
Company Remains Focused on Delivering Strong Second Half Performance
RATON, Fla., August 13, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.
Highlights included:
●Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026 quarter, resulting in part from the inability to record the sale of eight units in Q2 due to financing approval timing. This sale will be recognized in Q3.
●Customer adoption accelerated through expanding engagement with independent practices, larger physician groups, and health systems.
●Sales pipeline strengthened following CPT code implementation, supported by increasing physician education, inbound customer inquiries and commercial activity.
proposed a 26% increase in the hospital-based SRT delivery code, which, if finalized, would further improve provider economics and support expanded adoption of SRT across hospital and health system settings.
●International commercial activity expanded across key Asia-Pacific markets, including Australia and New Zealand, supporting future growth opportunities.
●Active website users increased 153% year-over-year.
●Company remains committed to delivering strong performance during the second half of 2026.
Management Commentary
“While our reported second quarter revenue was impacted by the timing of financing approvals for eight units, our commercial execution remained strong throughout the quarter. Those units have since been sold and related revenue will be recognized in Q3. The delayed financing approval affected the timing of revenue recognition, not customer demand or commercial execution,” said Joseph Sardano, Chairman and Chief Executive Officer.
“Importantly, we are seeing the benefits of the dedicated CPT codes reflected in growing physician engagement, expanding customer interest, and a strengthening sales pipeline. During the quarter, we broadened relationships with larger physician groups, increased utilization under our Fair Deal Agreement program, and advanced our commercial initiatives in both the U.S. and internationally. In addition, we were particularly encouraged by the level of engagement we experienced across key Asia-Pacific markets, including Australia and New Zealand, where growing awareness of SRT is creating attractive long-term opportunities.
“We entered the third quarter with a healthy pipeline, growing customer engagement, and increasing commercial activity across both our domestic and international markets. We remain encouraged by the momentum we are seeing across the business and focused on executing against our five strategic priorities for 2026 - education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability,” concluded Sardano.
Second Quarter 2026 Financial Results
Revenues were $2.3 million for the three months ended June 30, 2026, compared to $7.3 million for the three months ended June 30, 2025, a decrease of $5.0 million, or 68.5%. The decrease in revenue was primarily driven by a lower number of units sold (11 in the three months ended June 30, 2026, including Fair Deal Agreements and rentals, compared to 19 in the three months ended June 30, 2025), reflecting no sales in the current period to a historically large customer. In addition, some systems placed during the quarter were under the Fair Deal Agreement program and rental arrangements, for which revenue is recognized over the term of the agreement rather than at the time of shipment.
Cost of sales was $1.5 million for the three months ended June 30, 2026, compared to $4.4 million for the three months ended June 30, 2025, a decrease of $2.9 million, or 65.9%. The decrease in cost of sales was primarily related to the lower number of units sold.
Gross profit was $0.8 million for the three months ended June 30, 2026, compared to $2.9 million for the three months ended June 30, 2025, a decrease of $2.1 million, or 72.4%. Our overall gross profit percentage was 34.8% in the three months ended June 30, 2026, compared to 39.7% in the corresponding period in 2025. The d
May 7, 2026 · 100% conf.
1D
-22.15%
$3.27
Act: -27.06%
5D
-19.71%
$3.37
Act: -13.95%
20D
-29.23%
$2.97
Act: -35.64%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784726087.362f9213
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
This page provides Sensus Healthcare Inc. (SRTS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on SRTS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.